Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose ...
MMRd showed no meaningful association with pOR, pCR, or RFS, suggesting limited utility for selecting patients for Gem-iDRS ...
Preliminary results from a preclinical study demonstrated statistically significant increase in MHC-I expression following ...
Cancer immunotherapy has saved lives, but it often falls short due to off-target toxicity and weak tumor-specific immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results